YMAB – y-mabs therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $23.00 price target on the stock.
Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth [Yahoo! Finance]
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... [Yahoo! Finance]
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
Form SC 13G/A Y-mAbs Therapeutics, Filed by: Paradigm Biocapital Advisors LP
Form SC 13G/A Y-mAbs Therapeutics, Filed by: VANGUARD GROUP INC
Form 10-Q Y-mAbs Therapeutics, For: Sep 30
Form 8-K Y-mAbs Therapeutics, For: Nov 08
Form SC 13G/A Y-mAbs Therapeutics, Filed by: VANGUARD GROUP INC
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.